Opinion
Video
Incorporating Real-World Evidence for HER2+ NSCLC
Key Takeaways
- Real-world evidence enhances understanding of HER2-directed therapies' effectiveness and safety in diverse populations, complementing clinical trial data.
- Collaboration among payers, providers, and manufacturers is vital for equitable access to HER2-directed therapies and cost management.
Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.
Video content above is prompted by the following:
- What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
- (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Related Videos
Related Content
October 25th 2024
